Clinical trials: Facial Papulopustular Rosacea
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Papular-pustular Rosacea, Papulopustular Rosacea (PPR)
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
- Conditions
- Papular-pustular Rosacea, Papulopustular Rosacea (PPR), Papulopustular Rosacea
- Trial name
- NCT06952517
- Testing
- Clascoterone Cream 1%
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Narrows Institute for Biomedical Research
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Rosacea, Papulopustular
Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device
10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device
- Trial name
- NCT05592548
- Testing
- cold atmospheric plasma
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Skin Center Dermatology Group
Rosacea, Papulopustular, Rosacea, Erythematotelangiectatic
Rosacea Radiofrequency Microneedling
There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for…
- Trial name
- NCT06801717
- Testing
- KTP Laser Therapy, Radiofrequency microneedling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Miami
Rosacea
Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea
This is a double blind single site vehicle controlled study. The following activities will be conducted at each visit. Baseline Research Center Visit Obtain a signed and dated, written ICF prior to any study-related procedures.·…
- Trial name
- NCT05278624
- Testing
- Roflumilast Cream
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dermatology Consulting Services, PLLC
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- Trial name
- NCT02268474
- Testing
- 532nm KTP Laser vs 595nm Pulse Dye Laser
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Facial Papulopustular Rosacea
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT03142451
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 54 sites in United States
- Volunteers
- 751 people
- Sponsor
- Vyne Therapeutics Inc.